Encorafenib
Braftovi (encorafenib) is a small molecule pharmaceutical. Encorafenib was first approved as Braftovi on 2018-06-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms and melanoma. Braftovi's patents are valid until 2033-08-05 (FDA).
| Trade Name | Braftovi |
|---|---|
| Common Name | Encorafenib |
| Indication | colorectal neoplasms, melanoma |
| Drug Class | Raf kinase inhibitors |
